HC Wainwright Analysts Cut Earnings Estimates for NovoCure

NovoCure Limited (NASDAQ:NVCR) – Stock analysts at HC Wainwright lowered their FY2029 EPS estimates for shares of NovoCure in a report issued on Thursday, July 23rd. HC Wainwright analyst E. Bodnar now forecasts that the medical equipment provider will earn $1.90 per share for the year, down from their previous estimate of $1.95. The consensus estimate for NovoCure’s current full-year earnings is ($1.52) per share.

Several other analysts have also recently commented on NVCR. Evercore reaffirmed an “outperform” rating on shares of NovoCure in a research report on Friday, May 1st. Wedbush increased their price objective on NovoCure from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Friday. Weiss Ratings upgraded NovoCure from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 1st. Zacks Research cut NovoCure from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Finally, Wells Fargo & Company lifted their target price on shares of NovoCure from $13.50 to $17.00 and gave the company an “equal weight” rating in a research note on Monday, May 4th. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $21.20.

NovoCure Price Performance

Shares of NASDAQ:NVCR opened at $17.65 on Friday. The company’s fifty day moving average is $16.64 and its two-hundred day moving average is $14.14. The company has a quick ratio of 2.70, a current ratio of 2.90 and a debt-to-equity ratio of 0.71. NovoCure has a 12-month low of $9.82 and a 12-month high of $21.45. The company has a market cap of $2.04 billion, a P/E ratio of -13.58 and a beta of 0.94.

NovoCure (NASDAQ:NVCR) last posted its quarterly earnings data on Thursday, July 23rd. The medical equipment provider reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.20. NovoCure had a negative net margin of 21.25% and a negative return on equity of 44.02%. The firm had revenue of $183.58 million during the quarter, compared to analyst estimates of $172.44 million. During the same quarter last year, the business posted ($0.36) EPS. The company’s revenue was up 15.6% on a year-over-year basis.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Handelsbanken Fonder AB lifted its stake in shares of NovoCure by 37.2% in the 2nd quarter. Handelsbanken Fonder AB now owns 51,223 shares of the medical equipment provider’s stock valued at $776,000 after purchasing an additional 13,900 shares during the last quarter. Amundi lifted its holdings in NovoCure by 19.9% in the 1st quarter. Amundi now owns 47,583 shares of the medical equipment provider’s stock worth $519,000 after purchasing an additional 7,907 shares during the last quarter. California State Teachers Retirement System boosted its position in NovoCure by 43.6% during the first quarter. California State Teachers Retirement System now owns 142,561 shares of the medical equipment provider’s stock worth $1,554,000 after purchasing an additional 43,257 shares during the period. Eversept Partners LP grew its holdings in NovoCure by 11.5% during the first quarter. Eversept Partners LP now owns 134,917 shares of the medical equipment provider’s stock valued at $1,471,000 after purchasing an additional 13,939 shares during the last quarter. Finally, Quantinno Capital Management LP grew its holdings in NovoCure by 23.7% during the first quarter. Quantinno Capital Management LP now owns 2,487,376 shares of the medical equipment provider’s stock valued at $27,112,000 after purchasing an additional 477,128 shares during the last quarter. Institutional investors own 84.61% of the company’s stock.

Insider Buying and Selling at NovoCure

In related news, Director Allyson J. Ocean sold 2,945 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $15.77, for a total value of $46,442.65. Following the completion of the sale, the director owned 11,324 shares of the company’s stock, valued at approximately $178,579.48. The trade was a 20.64% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director W Anthony Vernon sold 2,945 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $15.77, for a total value of $46,442.65. Following the completion of the transaction, the director owned 197,657 shares in the company, valued at $3,117,050.89. This represents a 1.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 51,943 shares of company stock worth $893,171 over the last quarter. Insiders own 5.52% of the company’s stock.

Key NovoCure News

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: NovoCure reported Q2 EPS of -$0.13, beating the consensus loss estimate of -$0.33, while revenue came in at $183.6 million versus expectations of $172.4 million. Revenue also rose 15.6% year over year, signaling improving business momentum.
• Positive Sentiment: The company raised its FY2026 revenue guidance to $710 million-$725 million, above the market’s prior expectation of about $704 million, which suggests management sees continued demand strength.
• Positive Sentiment: HC Wainwright increased its price target on NovoCure to $52 from $46 and maintained a Buy rating, reinforcing optimism around the company’s longer-term earnings potential. Article Title
• Neutral Sentiment: Wedbush also raised its price target to $20 from $18, but kept a Neutral rating, indicating improved expectations without a strong bullish call. Article Title
• Neutral Sentiment: Shares also got a lift from optimism around the company’s brain therapy pipeline and possible FDA-related catalysts, which helped push the stock to new highs as investors priced in further upside. Article Title
• Negative Sentiment: HC Wainwright trimmed its FY2029 EPS estimate slightly to $1.90 from $1.95, a small caution on the company’s very long-term earnings outlook.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.